Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07378293

Effects of Selected Statins on Blood Glucose Levels in Healthy Volunteers

Effects of Selected Statins on Blood Glucose Levels in Healthy Volunteers: A Randomized Phase I Clinical Trial

Status
Not Yet Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Shaheed Benazir Bhutto University Sheringal Dir Upper · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This Phase I randomized clinical trial aims to investigate the short-term effects of three commonly prescribed statins (atorvastatin, rosuvastatin, and simvastatin) at different dose levels on blood glucose homeostasis in healthy volunteers. The study will assess changes in fasting blood glucose, insulin, and C-peptide levels following two days of statin administration under controlled conditions. The research seeks to provide comparative data on the potential diabetogenic effects of these medications.

Detailed description

This study addresses emerging evidence suggesting statin therapy may modestly increase diabetes risk in a dose-dependent manner. The trial will enroll healthy volunteers who will be randomized to receive one of three statins at low, moderate, or high doses for two days. Blood glucose will be measured using standardized glucometers, while insulin and C-peptide levels will be determined using ELISA assays. The study aims to clarify whether different statins have varying effects on glucose metabolism during short-term exposure and to establish dose-response relationships.

Conditions

Interventions

TypeNameDescription
DRUGSimvastatin (10mg, 20mg, 40mg)The Simvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days
DRUGRosuvastatin (5mg, 20mg, 40mg)The Rosuvastatin (5mg, 20mg, 40mg) group participants will be given the drug orally OD for two days
DRUGAtorvastatin (10mg, 20mg, 40mg)The Atorvastatin (10mg, 20mg, 40mg) group participants will be given the drug orally OD for two days

Timeline

Start date
2026-03-01
Primary completion
2026-12-30
Completion
2027-02-20
First posted
2026-01-30
Last updated
2026-01-30

Locations

2 sites across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07378293. Inclusion in this directory is not an endorsement.